Foster City, Calif. - Gilead announced it will not pursue a marketing authorization for Descovy(emtricitabine 200 mg/tenofovir alafenamide 25 mg) for pre-exposure prophylaxis (PrEP) in the European Union (EU) at this time. Conversations with healthcare professionals, payers and other stakeholders across Europe have confirmed there is a lack of demand for innovative daily PrEP options given the broad availability of generic alternatives. Policies and decisions made by national governments relating to reimbursement can adversely impact the feasibility of pursuing marketing authorization in each market. This is the case in the EU.

Gilead also announced it will submit a study protocol amendment to local EU health authorities to extend the DISCOVER trial, a multi-year global Phase 3 registrational clinical trial evaluating the safety and efficacy of once-daily Descovy for PrEP compared with Truvada(emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets; F/TDF) (Truvada for PrEP), in men and transgender women who have sex with men and may benefit from PrEP medicines. The proposed DISCOVER extension will go through September 2027 and will provide 264 weeks (five years) of additional data (with nearly eight years of Descovy open label extension), to further inform clinical and reimbursement decisions regarding daily oral PrEP options and allow current DISCOVER participants to retain access to Descovy for PrEP.

Gilead remains deeply committed to scientific innovation and the development of novel PrEP options with the goal of achieving zero new HIV infections. To help ensure sustainable access to new PrEP options for all who can benefit, we will continue to pursue marketing authorizations in countries where payers recognize the public health and individual value of HIV prevention.

For information about the approved uses and important safety information for Descovy (emtricitabine and tenofovir alafenamide; 200/25 mg), and for Truvada (emtricitabine and tenofovir disoproxil fumarate; 200/300 mg), please see the full Prescribing Information including BOXED WARNINGS for each product, available at Gilead.com.

Please see below for U.S. Indications and Important Safety Information, including Boxed Warnings, for Descovy for PrEP and Truvada for PrEP.

There is no cure for HIV or AIDS.

U.S. Indication for Descovy for PrEP

Descovy for PrEP is indicated in at-risk adults and adolescents (?35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. HIV-1-negative status must be confirmed immediately prior to initiation.Limitation of Use:

Descovy for PrEP is not indicated in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

For more than 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention, testing and linkage to care, and cure research. Today, it's estimated that more than 12 million people living with HIV globally receive antiretroviral therapy provided by Gilead or one of the company's manufacturing partners.

Gilead is committed to supporting the global health community to quickly and effectively respond to serious and life-threatening viral outbreaks worldwide. To that end, we are contributing our antiviral expertise and resources to help investigate potential treatments for patients with COVID-19. For more information on Gilead's response to the coronavirus outbreak please visit the company's dedicated page: https://www.gilead.com/purpose/advancing-global-health/covid-19.

Forward-Looking Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility of unfavorable results from ongoing and additional clinical trials involving Descovy for PrEP, Truvada for PrEP, and the possibility that we are unable to complete one or more of such trials in the currently anticipated timelines or at all. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

Contact:

Foster City, CA

Headquarters

333 Lakeside Drive

Foster City, CA 94404

Phone: +1 650 574 3000

Fax: (650) 578-9264

1-800-GILEAD-5 (1-800-445-3235)

(C) 2021 Electronic News Publishing, source ENP Newswire